Autoimmune Disease: The 10 Major Types & Integrative Approaches Using Repurposed Drugs, Herbal Supplements & Cannabinoids

Introduction

Autoimmune disease occurs when the immune system — designed to protect the body from foreign invaders — mistakenly attacks the body's own tissues. With over 80 recognized autoimmune conditions affecting an estimated 50 million Americans, these diseases represent one of the most significant and underappreciated chronic disease burdens of our time.

Despite their diversity, autoimmune diseases share a common thread: dysregulated immune activity, chronic inflammation, and oxidative stress. This shared pathology creates a compelling rationale for broad-spectrum anti-inflammatory and immunomodulatory strategies — including repurposed pharmaceutical agents, botanical compounds, and cannabinoids — as adjunctive or foundational therapeutic tools.

This article provides an in-depth overview of the 10 major autoimmune conditions, followed by a comprehensive review of integrative approaches supported by emerging research.

Part I: The 10 Major Autoimmune Diseases

1. Rheumatoid Arthritis (RA)

RA is a chronic, systemic inflammatory disorder primarily targeting synovial joints, leading to cartilage and bone destruction. Key drivers include autoreactive T-cells and B-cells producing rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA), alongside elevated TNF-α, IL-1β, and IL-6. Beyond joints, RA carries significant cardiovascular, pulmonary, and neurological comorbidity risk.

2. Systemic Lupus Erythematosus (SLE)

Lupus is a multisystem autoimmune disease characterized by autoantibody production (particularly anti-dsDNA and anti-Smith antibodies), immune complex deposition, and complement activation. It can affect the skin, kidneys (lupus nephritis), heart, lungs, brain, and joints. Flares are driven by dysregulated type I interferon signaling and B-cell hyperactivity.

3. Multiple Sclerosis (MS)

MS is an immune-mediated demyelinating disease of the central nervous system. Autoreactive T-cells breach the blood-brain barrier and attack myelin, leading to lesions, neurodegeneration, and progressive disability. Elevated TNF-α, IL-17, and IFN-γ drive the inflammatory cascade. (See our dedicated MS/TM/NMOSD deep-dive article for full detail.)

4. Hashimoto's Thyroiditis

The most common cause of hypothyroidism in developed countries, Hashimoto's involves lymphocytic infiltration of the thyroid gland and production of anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin antibodies. Chronic thyroid inflammation leads to progressive glandular destruction and hormonal insufficiency, with downstream effects on metabolism, cognition, mood, and cardiovascular health.

5. Type 1 Diabetes (T1D)

T1D results from autoimmune destruction of insulin-producing beta cells in the pancreatic islets of Langerhans, mediated by autoreactive CD8+ T-cells and supported by CD4+ T-helper cells. The result is absolute insulin deficiency. Emerging research implicates gut dysbiosis, viral triggers (particularly enteroviruses), and environmental factors in disease initiation.

6. Inflammatory Bowel Disease (IBD) — Crohn's & Ulcerative Colitis

IBD encompasses Crohn's disease (transmural inflammation affecting any GI segment) and ulcerative colitis (mucosal inflammation confined to the colon). Both involve dysregulated mucosal immunity, gut barrier dysfunction, and aberrant responses to commensal microbiota. Elevated IL-6, TNF-α, IL-12, and IL-23 drive chronic intestinal inflammation with systemic extraintestinal manifestations.

7. Psoriasis & Psoriatic Arthritis

Psoriasis is a chronic inflammatory skin condition driven by IL-17A, IL-23, and TNF-α, resulting in keratinocyte hyperproliferation and characteristic plaques. Up to 30% of psoriasis patients develop psoriatic arthritis, an inflammatory joint disease with features overlapping RA and ankylosing spondylitis. The Th17 axis is central to both conditions.

8. Celiac Disease

Celiac disease is a T-cell mediated autoimmune enteropathy triggered by dietary gluten in genetically susceptible individuals (HLA-DQ2/DQ8). Gluten peptides activate innate and adaptive immune responses in the small intestinal mucosa, leading to villous atrophy, malabsorption, and systemic inflammation. Untreated celiac significantly increases risk of other autoimmune conditions, lymphoma, and neurological complications.

9. Myasthenia Gravis (MG)

MG is a neuromuscular junction disorder caused by autoantibodies against acetylcholine receptors (AChR) or muscle-specific kinase (MuSK), impairing neuromuscular transmission and causing fatigable muscle weakness. The thymus plays a central pathogenic role — thymoma is present in ~15% of cases. Complement activation and T-cell dysregulation are key mechanistic drivers.

10. Sjögren's Syndrome

Sjögren's is a systemic autoimmune disease primarily targeting exocrine glands (salivary and lacrimal), causing dry eyes and dry mouth, but with significant systemic manifestations including fatigue, neuropathy, vasculitis, and lymphoma risk. Anti-Ro/SSA and anti-La/SSB antibodies are hallmark biomarkers. B-cell hyperactivation and type I interferon dysregulation are central to pathogenesis.

Part II: The Shared Inflammatory Architecture

Despite their clinical diversity, these 10 conditions share key pathological features that inform integrative therapeutic strategies:

• Th17/Treg imbalance — excess pro-inflammatory Th17 cells relative to regulatory T-cells (Tregs)
• NF-κB and STAT3 hyperactivation — master transcription factors driving cytokine production
• Elevated IL-6, TNF-α, IL-1β, IL-17, and IL-23
• Oxidative stress and mitochondrial dysfunction
• Gut dysbiosis and leaky gut — disrupted intestinal barrier amplifying systemic immune activation
• Molecular mimicry — microbial or environmental antigens triggering cross-reactive autoimmunity

Part III: Repurposed Pharmaceutical Agents

Low Dose Naltrexone (LDN)

LDN (1.5–4.5 mg/day) is arguably the most versatile repurposed agent in autoimmune disease. Via transient opioid receptor blockade and TLR4 antagonism, LDN suppresses microglial and macrophage activation, reduces TNF-α, IL-6, and IL-12, and promotes Treg expansion. Clinical evidence supports its use in MS, Crohn's disease, fibromyalgia, and lupus, with an excellent safety profile and low cost. LDN's ability to restore immune homeostasis without broad immunosuppression makes it particularly valuable in autoimmune conditions where infection risk is a concern.

Ivermectin

Beyond its antiparasitic origins, ivermectin demonstrates potent NF-κB inhibition, NLRP3 inflammasome suppression, and reduction of IL-6, TNF-α, and IL-1β. Its potential role in autoimmune disease is supported by the molecular mimicry hypothesis — parasitic infections and their resolution may modulate immune tolerance — and by direct anti-inflammatory mechanisms relevant to RA, IBD, and psoriasis. Makis et al. have highlighted ivermectin's broad immunomodulatory and potential anti-neoplastic properties.

Mebendazole

Mebendazole's tubulin-targeting mechanism disrupts inflammatory cell migration and proliferation. Its inhibition of HIF-1α reduces hypoxia-driven inflammation relevant to synovitis in RA and intestinal inflammation in IBD. Wnt/β-catenin modulation offers additional neuroprotective and anti-proliferative benefits. Noori et al. have noted mebendazole's capacity to reduce inflammatory infiltration across multiple tissue types.

Niclosamide

Niclosamide's STAT3 inhibition is particularly relevant to autoimmune disease, as STAT3 drives Th17 differentiation and IL-6 signaling — both central to RA, psoriasis, IBD, and lupus. Its mTOR inhibition promotes autophagy and cellular homeostasis, while NF-κB suppression reduces global inflammatory tone. Seyyedabadi et al. have highlighted STAT3 as a high-value therapeutic target across autoimmune conditions.

DMSO (Dimethyl Sulfoxide)

DMSO's free radical scavenging, anti-inflammatory, and membrane-penetrating properties make it a valuable adjunct across autoimmune conditions. Its ability to reduce prostaglandin and histamine-mediated inflammation, combined with its carrier function for co-administered agents, supports its use topically (for psoriasis, RA joint inflammation) and systemically. Cairns et al. have noted DMSO's underutilized potential in inflammatory and autoimmune disease management.

Part IV: Cannabinoids — CBD & THC

The endocannabinoid system (ECS) is a master regulatory network governing immune function, inflammation, pain, and cellular homeostasis. Both CBD (cannabidiol) and THC (tetrahydrocannabinol) interact with this system, offering significant therapeutic potential in autoimmune disease.

CBD (Cannabidiol)

CBD is non-psychoactive and exerts its effects through multiple mechanisms:

• CB2 receptor modulation → suppression of peripheral immune cell activation
• TRPV1 activation → anti-inflammatory and analgesic effects
• GPR55 antagonism → reduced osteoclast activity (relevant in RA)
• NF-κB and STAT3 suppression → reduced cytokine production
• Promotion of Tregs → restoration of immune tolerance
• Antioxidant activity → reduction of oxidative stress in inflamed tissues

Clinical and preclinical evidence supports CBD's use in RA (reduced joint inflammation and pain), IBD (mucosal healing and reduced intestinal inflammation), MS (spasticity and neuropathic pain), psoriasis (keratinocyte proliferation inhibition), and lupus (immune modulation). CBD's favorable safety profile and legal accessibility make it one of the most practical integrative additions to autoimmune protocols.

THC (Tetrahydrocannabinol)

THC, the primary psychoactive cannabinoid, acts primarily via CB1 and CB2 receptors:

• CB2 agonism → potent immunosuppressive effects on T-cells, B-cells, and macrophages
• Reduction of TNF-α, IL-6, and IFN-γ
• Analgesic and antispasmodic effects (particularly relevant in MS, RA, and IBD)
• Appetite stimulation → relevant in IBD and autoimmune-related cachexia
• Neuroprotective effects via CB1 receptor activation in CNS tissue

THC is most valuable in autoimmune conditions with significant pain, spasticity, or neuropathic components. Combined CBD:THC formulations (such as 1:1 or high-CBD ratios) often provide superior anti-inflammatory and analgesic outcomes compared to either cannabinoid alone, via the entourage effect.

Condition-Specific Cannabinoid Guidance

• RA — CBD topicals for joint inflammation + oral CBD/THC for systemic pain and sleep
• IBD — CBD oil (sublingual or encapsulated) for mucosal healing; THC for appetite and pain
• MS — CBD:THC combination for spasticity, neuropathic pain, and bladder dysfunction
• Psoriasis — CBD topicals for plaque reduction; oral CBD for systemic immune modulation
• Lupus — CBD for immune modulation and fatigue; low-dose THC for pain and sleep
• Hashimoto's — CBD for thyroid inflammation and anxiety; supports gut-thyroid axis
• Sjögren's — CBD for neuropathic pain and dryness-related discomfort

Part V: Herbal & Botanical Supplements

Curcumin (Turmeric)

Curcumin inhibits NF-κB, COX-2, and LOX pathways, reducing production of TNF-α, IL-1β, IL-6, and IL-17. It has demonstrated efficacy in RA (comparable to diclofenac in some trials), IBD (mucosal healing), psoriasis (Th17 suppression), and lupus (anti-dsDNA antibody reduction). Bioavailability is significantly enhanced with piperine (black pepper extract) or liposomal formulations.

Boswellia serrata

Boswellic acids (particularly AKBA) are potent 5-LOX inhibitors, reducing leukotriene production and inflammatory cell infiltration. Clinical evidence supports use in RA, IBD (Crohn's and UC), and psoriatic arthritis. Boswellia also inhibits complement activation — relevant in lupus and MG.

Quercetin

Quercetin modulates Th1/Th2/Th17 balance, inhibits mast cell degranulation, and suppresses NF-κB. It demonstrates particular utility in RA, IBD, and Sjögren's syndrome. Its ability to stabilize mast cells is relevant in conditions with significant histamine-driven inflammation.

Alpha-Lipoic Acid (ALA)

ALA is a mitochondrial antioxidant that reduces oxidative stress across all autoimmune conditions. It regenerates vitamins C and E, suppresses NF-κB, and improves insulin sensitivity (relevant in T1D and Hashimoto's-associated metabolic dysfunction). ALA has shown benefit in MS, diabetic neuropathy, and RA.

Omega-3 Fatty Acids (EPA/DHA)

EPA and DHA competitively inhibit arachidonic acid metabolism, reducing prostaglandin E2 and leukotriene B4 production. Clinical evidence supports their use in RA (reduced joint tenderness and morning stiffness), lupus (reduced disease activity), IBD, and psoriasis. High-dose fish oil (3–4g EPA+DHA/day) is typically required for anti-inflammatory effect.

Vitamin D3

Vitamin D3 is a potent immunomodulator that promotes Treg differentiation, suppresses Th17 activity, and reduces autoantibody production. Deficiency is strongly associated with increased risk and severity of virtually all autoimmune conditions. Optimal levels (60–80 ng/mL) should be targeted with D3 + K2 supplementation.

Ashwagandha (Withania somnifera)

Ashwagandha's withanolides suppress NF-κB and reduce cortisol-driven immune dysregulation. It demonstrates adaptogenic, anti-inflammatory, and thyroid-supportive properties — particularly relevant in Hashimoto's thyroiditis and autoimmune conditions with significant stress and fatigue components.

Berberine

Berberine activates AMPK, inhibits NF-κB and STAT3, and modulates the gut microbiome — addressing multiple autoimmune disease drivers simultaneously. It has shown benefit in T1D (beta cell protection), IBD (mucosal healing), RA, and psoriasis. Its gut microbiome-modulating effects are particularly relevant given the central role of dysbiosis in autoimmune pathogenesis.

Lion's Mane Mushroom

Lion's Mane stimulates NGF synthesis and demonstrates anti-neuroinflammatory properties via NF-κB suppression. It is particularly relevant in MS, MG, and autoimmune conditions with neurological involvement.

Palmitoylethanolamide (PEA)

PEA is an endogenous lipid mediator that activates PPAR-α, suppressing mast cell and macrophage activation. It reduces neuroinflammation, peripheral inflammation, and pain across multiple autoimmune conditions including MS, RA, IBD, and Sjögren's syndrome.

Part VI: Toward an Integrative Autoimmune Protocol

A foundational integrative approach applicable across autoimmune conditions:

• LDN (1.5–4.5 mg/day) — immune homeostasis, Treg promotion, microglial suppression
• CBD oil (25–75mg/day) — CB2 modulation, NF-κB suppression, Treg promotion
• THC (low dose, condition-dependent) — pain, spasticity, appetite, CB2 immunosuppression
• Curcumin (500–1000mg/day with piperine) — NF-κB, COX-2, IL-17 suppression
• Boswellia (300–500mg AKBA/day) — 5-LOX inhibition, complement modulation
• Omega-3 (3–4g EPA+DHA/day) — prostaglandin and leukotriene reduction
• Vitamin D3 (5000–10,000 IU/day + K2) — Treg promotion, Th17 suppression
• ALA (600mg/day) — mitochondrial antioxidant support
• Berberine (500mg 2–3x/day) — AMPK, STAT3, gut microbiome modulation
• Ivermectin / Mebendazole / Niclosamide — condition-specific, under medical supervision
• Dietary foundation — anti-inflammatory, low-glycemic, gluten-aware diet; consider ketogenic or autoimmune protocol (AIP) diet

Important: This article is for educational purposes only and does not constitute medical advice. All therapeutic decisions should be made in consultation with a qualified healthcare provider. Repurposed pharmaceutical agents should only be used under medical supervision.

Key References

• Cairns, D.M. et al. — Low dose naltrexone as an immunomodulatory agent across autoimmune conditions.
• Makis, W. et al. — Ivermectin: repurposing potential in inflammatory and autoimmune disease.
• Noori, S. et al. — Natural anti-inflammatory compounds in autoimmune and inflammatory conditions.
• Seyyedabadi, B. et al. — STAT3/IL-6 signaling as a therapeutic target in autoimmune disease.
• Seyfried, T.N. et al. — Mitochondrial metabolic dysfunction as a driver of chronic inflammation and autoimmunity.
• Andries, K. et al. — Gut-brain-immune axis modulation in autoimmune disease.